Fig. 6

Safety evaluation of NC therapy in comparison to their corresponding clinical formulations in healthy ICR mice. (A) The percentage of RBC hemolysis upon varying concentrations of the NC combinations was normalized to that with the positive control (Triton X-100). (B) Cytotoxicity of Pt^(IV)-NP and cisplatin in noncancerous BEAS-2B cells. (C) Bodyweight change was monitored during the observation after four injections of drugs. Healthy mice were intraperitoneally administered (1) saline; (2) FD combination (cisplatin, 3 mg/kg plus CPT-11, 2.9 mg/kg); (3) FD combination (cisplatin, 5 mg/kg plus CPT-11, 4.9 mg/kg); (4) FD combination (cisplatin, 8 mg/kg plus CPT-11, 7.8 mg/kg); (5) NC (3 mg/kg platinum equivalence plus 2 mg/kg SN38 equivalence); (6) NC (5 mg/kg platinum equivalence plus 3.3 mg/kg SN38 equivalence); and (7) NC (8 mg/kg platinum equivalence plus 5.3 mg/kg SN38 equivalence). The data are presented as the means ± SD (n = 6). (D-F) The spleen (D) and kidney (E) were excised and weighed and subsequently subjected to TUNEL staining (F) on Day 2 after the last administration. Scale bars, 50 μm